Society for Endocrinology Endocrine Emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy.
AuthorsHigham, Claire E
Cooksley, Timothy J
Lorigan, Paul C
Trainer, Peter J
AffiliationDepartment of Endocrinology, Christie Hospital NHS Foundation Trust, Manchester, University of Manchester, Manchester Academic Health Science Centre
MetadataShow full item record
AbstractImmunotherapy treatment with checkpoint inhibitors (CPI) (CTLA-4 and PD-1 inhibitors) significantly improves survival in a number of cancers. Treatment can be limited by immune-mediated adverse effects including endocrinopathies such as hypophysitis, adrenalitis, thyroiditis and diabetes mellitus. If endocrinopathies (particularly hypocortisolemia) are not recognized early, they can be fatal. The diagnosis and management of endocrinopathies can be complicated by simultaneous multi-organ immune adverse effects. Here, we present Endocrine Emergency Guidance for the acute management of the endocrine complications of checkpoint inhibitor therapy, the first specialty-specific guidance with Endocrinology, Oncology and Acute Medicine input and endorsed by the Society for Endocrinology Clinical Committee. We present algorithms for management: endocrine assessment and management of patients in the first 24 hours who present life-threateningly unwell (CTCAE grade 3-4) and the appropriate management of mild-moderately unwell patients (CTCAE grade 1-2) presenting with features compatible with an endocrinopathy. Other important considerations in relation to hypohysitis and the maintenance of glucocorticoid therapy are discussed.
CitationSociety for Endocrinology Endocrine Emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. 2018, 7(7): G1-G7 Endocr Connect
- [Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines].
- Authors: Castinetti F, Borson-Chazot F
- Issue date: 2019 May
- French Endocrine Society Guidance on endocrine side effects of immunotherapy.
- Authors: Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F
- Issue date: 2019 Feb
- Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
- Authors: González-Rodríguez E, Rodríguez-Abreu D, Spanish Group for Cancer Immuno-Biotherapy (GETICA).
- Issue date: 2016 Jul
- Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
- Authors: Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L
- Issue date: 2019 Feb 1
- The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
- Authors: Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH
- Issue date: 2018 Feb